Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Licensed Anti-Microbial Drugs Logical for Clinical Trials Against Pathogens Currently Suspected in Alzheimer's Disease

Version 1 : Received: 28 January 2021 / Approved: 29 January 2021 / Online: 29 January 2021 (13:57:18 CET)

A peer-reviewed article of this Preprint also exists.

Norins, L.C. Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease. Antibiotics 2021, 10, 327. Norins, L.C. Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease. Antibiotics 2021, 10, 327.

Abstract

There is now considerable evidence that several infectious agents (viruses, bacteria, or parasites) may play a contributing role in the development of Alzheimer’s disease (AD). The six primary suspects are herpes viruses, spirochetal bacteria, Chlamydia pneumoniae, Porphyromonas gingivalis, mycobacteria, and toxoplasma parasites. Also, some of the antimicrobial and antiviral agents that are used to treat them have shown promise for AD interventions. I describe this evidence and assert it is now time to accelerate clinical trials of these existing drugs, already federally approved, to determine if such treatments can delay, halt, or reverse AD.

Keywords

Alzheimer’s disease; dementia, beta-amyloid; germ theory; drug development; clinical trials; herpes; spirochetes; Chlamydia pneumoniae; Porphyromonas gingivalis; toxoplasma; mycobacteria

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.